Case Report: Dupilumab-associated psoriasiform eruption followed by depigmentation in a patient with prurigo nodularis and Vogt-Koyanagi-Harada disease
Dupilumab blocks interleukin (IL)-4 and IL-13 signaling and is effective for type 2 inflammatory diseases, including atopic dermatitis and prurigo nodularis. Paradoxical psoriasiform eruptions and, less commonly, new-onset or worsening vitiligo have be…